Quick Answer
Inhibikase Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2024.
Inhibikase Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $260.5K | +111.0% |
| 2022 | $123.4K | -96.0% |
| 2021 | $3.10M | +343.9% |
| 2020 | $698.5K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $79.6K | +991.3% | -31.6% |
| June 30, 2023 | $116.4K | +1676.7% | +80.4% |
| March 31, 2023 | $64.5K | +40.2% | +784.9% |
| September 30, 2022 | $7.3K | -97.8% | +11.3% |
| June 30, 2022 | $6.6K | -99.5% | -85.8% |
- Inhibikase Therapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2024 period, Inhibikase Therapeutics, Inc.’s total revenue has declined by 100.0% (from $698.5 thousand to $0.00).
- The most recent figure is from Inhibikase Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: